The A$5.9M R&D refund extends cash runway for a clinical-stage biotech with a $56M market cap, reducing near-term dilution risk. Monitor upcoming Phase 1/2 data readouts for pipeline catalysts — the refund buys time but does not change fundamental trial risk.
Price Chart
Executive Summary
Radiopharm Theranostics received a A$5.885M R&D tax refund for FY2025 from the Australian government's R&D tax incentive program. The cash injection provides non-dilutive funding for the company's clinical-stage radiopharmaceutical pipeline, extending its cash runway without shareholder dilution.
Key Facts
- Received A$5,885,131 R&D tax refund for FY2025, including A$104,475 interest
- Refund is from Australian Government's R&D tax incentive program with refundable tax offset up to 43.5%
- Provides non-dilutive funding for continued development of radiopharmaceutical pipeline
- Company is clinical-stage with one Phase 2 and five Phase 1 trials across lung, breast, and brain cancers
Financial Impact
A$5.885M cash injection (~10.5% of $56M market cap) provides non-dilutive funding for clinical pipeline
Risk Factors
- Clinical-stage company with no approved products — pipeline failure risk remains unchanged
- A$5.9M is modest relative to clinical trial costs; cash runway extension is limited
- No revenue from product sales — continued reliance on equity or debt financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-075197 |
| Document: ea0297034-6k_radiopharm.htm | 0001213900-26-075197 |
| Document: 0001213900-26-075197-index-headers.html | 0001213900-26-075197 |
| Document: 0001213900-26-075197-index.html | 0001213900-26-075197 |
| Document: 0001213900-26-075197.txt | 0001213900-26-075197 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9600 | awaiting T+5 | — | $0.9000 (−6.25%) |
Oct 26, 2026 1d ago | 6-K | $0.9960 | awaiting T+5 | — | $0.9000 (−9.64%) |
Oct 20, 2026 7d ago | 6-K | $0.9900 $0.9000 | ▼ −9.09% | ▼ −9.17% | $0.9000 (−9.09%) |
Oct 14, 2026 13d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9000 (−16.67%) |
Oct 5, 2026 22d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9000 (−29.13%) |
Oct 1, 2026 26d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9000 (−39.19%) |
Sep 30, 2026 27d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9000 (−44.44%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9000 (+42.74%) |
Sep 22, 2026 5w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9000 (−45.45%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9000 (−55.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers